Malarial Dihydrofolate Reductase as Drug Target

From Proteopedia

Revision as of 05:47, 28 November 2012 by Mary Smith (Talk | contribs)
Jump to: navigation, search

Introduction

There are currently antimalarial drugs that target the malarial dihydrofolate reductase (DHFR) such as pyrimethamine and cycloguanil. However, the effectiveness of these drugs has decreased because of mutations in the enzyme that have led to drug resistance. New research in drug development now incorporates both the wild-type as well as the quadruple mutant DHFR from the Plasmodium falciparum malarial strain.

Crystal structure of Wild-type PfDHFR-TS COMPLEXED WITH NADPH, dUMP AND PYRIMETHAMINE (PDB entry 3QGT)

Drag the structure with the mouse to rotate
N51I, C59R, S108N, and I164L. These mutations caused decreased binding affinities of inhibitors similar to pyrimethamine.

Proteopedia Page Contributors and Editors (what is this?)

Mary Smith, Alexander Berchansky, Karsten Theis, Michal Harel

Personal tools